Abstract
It has long been proposed that elevation of liver enzymes including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyltransferase (GGT) may be associated with insulin resistance (IR). In the present study, we aimed to investigate the association of the above mentioned liver enzymes with IR by using hyperinsulinemic euglycemic clamp, as well as their relationship with individual component of metabolic syndrome (MetS) in 95 newly diagnosed type 2 diabetes (T2DM) Chinese patients. All the diagnosed patients did not use drugs for treatment of diabetes or dyslipidemia previously and were divided into IR and non-IR groups. The results showed that IR group had significantly higher ALT, AST, and GGT (P < 0.01, P < 0.01, and P < 0.05, respectively) compared with non-IR group. According to the individual MetS component, ALT and AST were significantly increased in patients with high blood pressure compared with those without (both P < 0.001); ALT and GGT were increased in patients with high triglyceride (P < 0.05 and P < 0.01); AST was increased in patients with central obesity (P < 0.05). In correlation analysis, a significant association was found between the three liver enzymes and clamp insulin sensitivity index (all P < 0.001). In the linear regression analysis, ALT was the determinant of clamp ISI, independent of age, sex, BMI, and fasting and OGTT 2 h plasma glucose (P < 0.0001). In conclusion, liver enzymes, especially ALT, were significantly associated with IR according to direct clamp assessment, which were independent of the traditional risk factors in diabetic patients; and individual liver enzymes may have different relationship with individual component of MetS.
Similar content being viewed by others
References
S.D. Lidofsky, Curr. Diab. Rep. 8, 25–30 (2008)
A.J. Hanley, L.E. Wagenknecht, A. Festa, R.B. D’Agostino Jr., S.M. Haffner, Diabetes Care 30, 1819–1827 (2007)
C. Weyer, P.A. Tataranni, C. Bogardus, R.E. Pratley, Diabetes Care 24, 89–94 (2001)
C. Weyer, C. Bogardus, D.M. Mott, R.E. Pratley, J. Clin. Invest. 104, 787–794 (1999)
A.J. Hanley, K. Williams, A. Festa, L.E. Wagenknecht, R.B. D’Agostino Jr., S.M. Haffner, Diabetes 54, 3140–3147 (2005)
S.G. Wannamethee, L. Lennon, P.H. Whincup, Diabetes Care 28, 2913–2918 (2005)
M. Nannipieri, C. Gonzales, S. Baldi, R. Posadas, K. Williams, S.M. Haffner, M.P. Stern, E. Ferrannini, Diabetes Care 28, 1757–1762 (2005)
P. André, B. Balkau, S. Vol, M.A. Charles, E. Eschwège, DESIR Study Group, Diabetes Care 30, 2355–2361 (2007)
R.K. Schindhelm, J.M. Dekker, G. Nijpels, C.D. Stehouwer, L.M. Bouter, R.J. Heine, M. Diamant, Diabet. Med. 24, 430–435 (2007)
A.J. Hanley, K. Williams, A. Festa, L.E. Wagenknecht, R.B. D’Agostino Jr., J. Kempf, B. Zinman, S.M. Haffner, Diabetes 53, 2623–2632 (2004)
Y.S. Lee, Y.K. Cho, J.C. Pae, S.Y. Oh, M.S. Kang, J.H. Park, H.J. Kim, D.I. Park, C.I. Sohn, W.K. Jeon et al., Korean J. Hepatol. 12, 221–229 (2006)
Y.J. Lee, D.G. Kang, J.S. Kim, H.S. Lee, Vascul Pharmacol 48, 38–46 (2008)
S.K. Kogawa, T. Hayashi, Y. Nakamura, N. Harita, T. Yoneda, G. Endo, H. Kambe, Diabetes Care 31, 1230–1236 (2008)
E.S. Ford, M.B. Schulze, M.M. Bergmann, C. Thamer, H.G. Joost, H. Boeing, Diabetes Care 31, 1138–1143 (2008)
B. Vozarova, N. Stefan, R.S. Lindsay, A. Saremi, R.E. Pratley, C. Bogardus, P.A. Tataranni, Diabetes 51, 1889–1895 (2002)
Y. Miyake, H. Eguchi, K. Shinchi, T. Oda, S. Sasazuki, S. Kono, J. Hepatol. 38, 18–23 (2003)
N. Nakanishi, K. Suzuki, K. Tatara, Diabetes Care 27, 1427–1432 (2004)
C. Postic, J. Girard, J. Clin. Invest. 118, 829–838 (2008)
I.R. Hsu, S.P. Kim, M. Kabir, R.N. Bergman, Am. J. Clin. Nutr. 86, s867–s871 (2007)
L.A. Adams, Endocr. Res. 32, 59–69 (2007)
S. Bellentani, G.R. Dalle, A. Suppini, G. Marchesini, Hepatology 47, 746–754 (2008)
E. Ortega, J. Koska, A.D. Salbe, P.A. Tataranni, J.C. Bunt, J. Clin. Endocrinol. Metab. 91, 1419–1422 (2006)
M.M. Gabir, R.L. Hanson, D. Dabelea, G. Imperatore, J. Roumain, P.H. Bennett, W.C. Knowler, Diabetes Care 23, 1108–1112 (2000)
Y. Li, J.G. Wang, P.J. Gao, G.L. Wang, Y.S. Qian, D.L. Zhu, J.A. Staessen, Am. J. Hypertens. 19, 448–453 (2006)
Y. Zhang, X. Li, D. Zou, W. Liu, J. Yang, N. Zhu, L. Huo, M. Wang, J. Hong, P. Wu, G. Ren, G. Ning, J. Clin. Endocrinol. Metab. 93, 2559–2565 (2008)
S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin, D.J. Gordon, R.M. Krauss, P.J. Savage, S.C. Smith Jr., J.A. Spertus, F. Costa, Circulation 112, 2735–2752 (2005)
Acknowledgments
This study is supported by the grant from 973 Project (No. 2006 CB 503904), National Natural Science Foundation of China (No. 30725037 and No. 30700383), and 863 project (NO: 2006AA02A409).
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Yifei Zhang and Xi Lu have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Zhang, Y., Lu, X., Hong, J. et al. Positive correlations of liver enzymes with metabolic syndrome including insulin resistance in newly diagnosed type 2 diabetes mellitus. Endocr 38, 181–187 (2010). https://doi.org/10.1007/s12020-010-9369-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-010-9369-6